Results 11 to 20 of about 11,862,011 (403)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

Nature Reviews Rheumatology, 2022
Since the second version of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015, therapeutic options for psoriatic arthritis (PsA) have advanced considerably.
L. Coates, E. Soriano, N. Corp, H. Bertheussen, K. Callis Duffin, Cristiano B. Campanholo, J. Chau, L. Eder, D. Fernández-Ávila, Oliver FitzGerald, A. Garg, D. Gladman, N. Goel, Philip S Helliwell, M. Husni, D. Jadon, Arnon Katz, Dhruvkumar Laheru, J. Latella, Ying-Ying Leung, C. Lindsay, E. Lubrano, L. Mazzuoccolo, P. Mease, D. O'Sullivan, A. Ogdie, W. Olsder, P. Palominos, L. Schick, I. Steinkoenig, M. D. de Wit, D. A. van der Windt, A. Kavanaugh, Cristiano Oliver Dafna Philip M. Elaine Dhrukumar Ying-Ying Campanholo Fitzgerald Gladman Helliwell Husni Lahe, Cristiano B. Campanholo, Oliver FitzGerald, D. Gladman, Philip S Helliwell, Dhrukumar Laheru, Ying-Ying Leung, E. Lubrano, L. Mazzuoccolo, P. Mease   +42 more
semanticscholar   +1 more source

Therapeutic challenges in a case of psoriasis with nail onset [PDF]

, 2017
Nail psoriasis affects a large number of patients with psoriasis and has a major psychosocial impact. Furthermore, it may be regarded as a predictor of more severe forms of psoriasis and early sign of psoriatic arthritis.
Benea, Vasile, Georgescu, Simona R., Mitran, Cristina I., Mitran, Mădălina I., Sârbu, Maria I., Tampa, Mircea   +5 more
core   +11 more sources

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)

Frontiers in Medicine, 2023
IntroductionBrodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family.
Luigi Gargiulo, Luigi Gargiulo, Luciano Ibba, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Giuseppe Argenziano, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Chiara Franchi, Francesca Maria Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo Valerio Marzano, Angelo Valerio Marzano, Matteo Megna, Francesca Sampogna, Massimo Travaglini, Antonio Costanzo, Antonio Costanzo, Alessandra Narcisi   +28 more
doaj   +1 more source

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

Psoriasis, 2022
Bimekizumab, a novel humanized monoclonal IgG1 antibody that neutralizes both IL-17A and IL-17F, was recently approved the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
A. Ruggiero, L. Potestio, E. Camela, G. Fabbrocini, M. Megna   +4 more
semanticscholar   +1 more source

The Patient's Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy. [PDF]

, 2016
BackgroundPUVA treatment is photochemotherapy for psoriasis that combines psoralen with UVA radiation. Although PUVA is a very effective treatment option for psoriasis, there is an absence of patient resources explaining and demonstrating the process of ...
Abrouk, Michael, Bhutani, Tina, DaLovisio, Renee, Farahnik, Benjamin, Jose, Margareth V, Koo, John, Lee, Kristina M, Liao, Wilson, Nakamura, Mio, Singh, Rasnik K, Zhu, Tian Hao   +10 more
core   +7 more sources

Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis

Dermatology and Therapy, 2020
Introduction Although the efficacy of monotherapy with biologics for psoriasis is well established, many patients fail to achieve complete plaque clearance from their initial biologic treatment alone.
Jerry Bagel, Elise Nelson, James Zapata, Alexa Hetzel   +3 more
doaj   +1 more source

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis

Journal of the European Academy of Dermatology and Venereology, 2022
Psoriasis is a chronic systemic inflammatory disorder associated with several comorbidities in addition to the characteristic skin lesions. Metabolic syndrome (MetS) is the most frequent comorbidity in psoriasis and a risk factor for cardiovascular ...
JJ Wu, A. Kavanaugh, MG Lebwohl, R. Gniadecki, JF Merola   +4 more
semanticscholar   +1 more source

Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times

Dermatology and Therapy, 2020
With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course.
Nicholas D. Brownstone, Quinn G. Thibodeaux, Vidhatha D. Reddy, Bridget A. Myers, Stephanie Y. Chan, Tina Bhutani, Wilson Liao   +6 more
doaj   +1 more source

Sex-disaggregated population analysis in patients with hidradenitis suppurativa

Frontiers in Medicine, 2022
BackgroundHidradenitis suppurativa (HS) is a common chronic inflammatory skin disease, which affects both sexes.ObjectivesIdentification of sex-specific risk factors, comorbidity, clinical manifestations, and treatments in HS patients.MethodsA non ...
Robert Sabat, Robert Sabat, Athanasia Tsaousi, Kamran Ghoreschi, Kerstin Wolk, Kerstin Wolk, Sylke Schneider-Burrus, Sylke Schneider-Burrus   +7 more
doaj   +1 more source

THE TREATMENT OF PSORIASIS. [PDF]

The Lancet, 1895
n ...
openaire   +6 more sources